S_ary The 'growth fraction' of tumours can now be assessed on paraffin sections of tissues using the monoclonal antibody MIBI by a microwave antigen retnreval technique. The MIBI labelling index was studied using a CAS 200 image analyser in 177 tumours from women with pnrmary operable breast carcinoma in whom long-term follow-up data were known. Statistical analysis showed a strong association between the MIBI labelling index and histological grade (P <0.001), tumour size (P =0.002). tumour type (P <0.001) and also patient survival (P <0.001). No association with lymph node stage (P = 0.59), local (P = 0.974) or regional recurrence (P = 0.185), the presence or absence of distant metastases (P = 0.418), patient age (P = 0.309), menopausal status (P = 0.181) or oestrogen receptor status (P = 0.401) was found in this group of patients. In multivariate analysis for survival, when histological grade. lymph node stage and tumour size were included as well as the MIBI labelling index, each was found to be of independent significance. If histological grade was not included, MIBI replaced it as the most important variable predicting for survival in this group of patients. The results suggest that the tumour growth fraction, as assessed by the MIBI labelling index, is an important predictor of survival.
An assessment of the growth fraction of a tumour may be performed by immunohistochemical staining of frozen section matenral using Ki-67 monoclonal antibody (Gerdes, et al., 1983 (Gerdes, et al., , 1984 . This reacts with a proliferation-associated antigen which is expressed in all cells not in Go phase of the cell cycle. Many authors have produced data suggesting that an assessment of the percentage of cells showing immunoreactivity with Ki-67 antibody correlates with other methods of determining the rate of growth of a malignant tumour such as S-phase fraction assessed by flow cytometry and mitotic count (Walker and Camplejohn, 1988; Dawson et al., 1990; Isola et al., 1990; Kennedy et al., 1992) , as well as thymidine labelling index (Karmel et al., 1989) and 5-bromodeoxyuridine labelling (Sasaki et al., 1988) . More recently, several other antibodies have been described which have been advocated as effectively demonstrating proliferating cells in formalin-fixed tissue including anti-proliferating cell nuclear antigen (PCNA), Ki-SI and MIBI. MIBI is raised against recombinant parts of the Ki-67 antigen and can be used on microwave-processed, paraffin-embedded tissue (Cattoretti et al., 1992) . This antibody appears to be superior to others for assessing tumour proliferation on routinely fixed and processed material not only because of the simplicity of the technique but because good correlation with Ki-67 expression on frozen material has also been reported (McCormick et al., 1993a,b) .
In breast carcinomas, although some have found no association between Ki-67 immunoreactivity and other prognostic variables (Stumpp et al., 1992) , many authors have reported an association with histological grade (Walker and Camplejohn, 1988; Betta et al., 1989; Bouzubar et al., 1989; Wrba et al., 1989; Dawson et al., 1990) . Associations with lymph node status (Wrba et al., 1989 ), patient's age (Sahin et al., 1991) , tumour size (Wrba et al., 1989; Veronese and Gambacorta, 1991) , oestrogen and progesterone receptor status (Wrba et al., 1989; Campani et al., 1991; Di-Stefano et al., 1991; Veronese and Gambacorta, 1991) , ploidy (Dawson et al., 1990; Isola et al., 1990; Lee et al., 1992) , p53 (Barbareschi et al., 1992) (1991) showed that the response to endocrine therapy of a breast carcinoma was related to the degree of Ki-67 immunoreactivity, and an association between Ki-67 staining and both disease-free interval and survival has been reported (Veronese et al., 1993) . However, few studies have been performed which have assessed the percentage of tumour cells expressing the Ki-67 antigen from patients with long-term follow-up because of the difficulty in obtaining sufficient archival frozen tissue.
The aim of this study was to assess immunoreactivity with the Ki-67-equivalent MIBI monoclonal antibody in a series of women with primary breast carcinoma in whom long-term follow-up and information on many other vanrables were available. Staining was assessed semiobjectively using a Cell Analysis System (CAS) 200 image analyser (Bacus and Grace, 1987) .
Materials and methods

Patients
Sections from the tumours of 177 women with primary operable breast carcinoma were assessed. These patients were all cared for by one surgical team under the supervision of RW Blamey and had had either wide local excision or simple mastectomy, with or without local radiotherapy, but had received no systemic adjuvant treatments. The tumours were all less than 5 cm in maximum extent and were not deeply fixed. Lymph node sampling was performed at the time of initial surgery (Blamey et al., 1980) . All patients were followed up every 3 months for 24 months, then 6 monthly to 5 years and annually thereafter. The patient's age, menopausal status and oestrogen receptor status, as assessed by a dextran charcoal coated technique (Nicholson et al., 1981) , were also known.
Tissue
The maximum dimension of the tumour was measured in the fresh stage and then confirmed after fixation when multiple sections were taken for routine processing. The histological The three categories of MIBI immunoreactivity also showed a strong association with overall survival (Figure 1 ). Those patients with carcinomas which demonstrated less than 17% nuclear area immunoreactivity had a significantly better survival than those showing 17-34% nuclear positivity. and those women with a high MIBl labelling index (> 34%) had the poorest survival.
Multivariate analysis (Table II) al., 1993b) . McCormick et al. (1993b) suggest that, because of this, the examination of MIB1 is superior to the immunohistochemical assessment of other cell proliferation antigens such as PCNA and Ki-Sl, which are present at low levels in non-cycling cells.
We demonstrate here similar biological associations with MIB1 labelling index in primary breast carcinomas to those described by many groups with S-phase fraction, thymidie labelling and cell cycle analysis by flow cytometry. The strong association between the extent of nuclear area staining with MIBI antibody and histological grade is similar to that we have reported previously with Ki-67 (Bouzubar et al., 1989) and which has been noted by others (Walker and Camplejohn, 1988; Betta et al., 1989; Wrba et al., 1989; Dawson et al., 1990 ). This correlation with histological grade is strong; however, in multivariate analysis MIBI labellng is of indepenent prognostic sign . When histological grade is excuded from the analysis, MIBI positivity replac it as the factor of most importance in predicting for survival. Thus, the MIBI labelling index and an assnent of histologcal grade appear to be complementary rather than equvalent prognostic factors.
As in the previous sudy in which 
